Assessment of hemostatic risk factors in predicting arterial thrombotic events

被引:96
作者
Feinbloom, D
Bauer, KA
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA
关键词
arterial; thrombosis; atherosclerosis; hemostasis; risk factors;
D O I
10.1161/01.ATV.0000181762.31694.da
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Arterial thrombosis results from endovascular injury and, to a lesser extent, alterations in hemostatic equilibrium. Although multiple hereditary and acquired hemostatic risk factors have been described in the pathophysiology of venous thrombosis, the degree and type of abnormalities that contribute to arterial thrombosis are less well understood. Endothelial cell injury with the elaboration of proinflammatory mediators stimulates the process of arterial thrombosis. Although this is most often the result of endovascular injury attributable to atherosclerotic disease, other disease states can elicit a similar response as well. Similarly, once thrombosis has been initiated, variations in the activity of coagulation proteins and endogenous anticoagulants, as well as the kinetics of platelet aggregation, may alter the effectiveness of thrombus formation. Epidemiological studies have identified several acquired or inherited states that may result in endothelial damage or altered hemostatic equilibrium, thereby predisposing patients to arterial thrombosis. These include hyperhomocysteinemia, elevated C-reactive protein, antiphospholipid antibodies, elevated fibrinogen, Factor VII, plasminogen activator inhibitor-1 (PAI-1), hereditary thrombophilias, and platelet hyper-reactivity. This review explores our present understanding of these risk factors in the development of arterial thrombotic events. At present, the literature supports a role for hyperhomocysteinemia, elevated C-reactive protein, and elevated fibrinogen as risk factors for arterial thrombosis. Similarly, the literature suggests that lupus anticoagulants and, to a lesser extent, elevated titers of cardiolipin IgG antibodies predispose to arterial vascular events. In certain subsets of patients, including those with concomitant cardiac risk factors, < 55 years of age, and women, hereditary thrombophilias such as carriership of the factor V Leiden and the prothrombin G20210A mutations may confer a higher risk of arterial thrombosis. However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking.
引用
收藏
页码:2043 / 2053
页数:11
相关论文
共 128 条
  • [11] Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation - A gene targeting and gene transfer study in mice
    Carmeliet, P
    Moons, L
    Lijnen, HR
    Janssens, S
    Lupu, F
    Collen, D
    Gerard, RD
    [J]. CIRCULATION, 1997, 96 (09) : 3180 - 3191
  • [12] Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells
    Chen, YQ
    Su, M
    Walia, RR
    Hao, Q
    Covington, JW
    Vaughan, DE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) : 8225 - 8231
  • [13] Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis
    Clarke, R
    Collins, R
    Lewington, S
    Donald, A
    Alfthan, G
    Tuomilehto, J
    Arnesen, E
    Bonaa, K
    Blacher, J
    Boers, GHJ
    Bostom, A
    Bots, ML
    Grobee, DE
    Brattström, L
    Breteler, MMB
    Hofman, A
    Chambers, JC
    Kooner, JS
    Coull, BM
    Evans, RW
    Kuller, LH
    Evers, S
    Folsom, AR
    Freyburger, G
    Parrot, F
    Genst, J
    Dalery, K
    Graham, IM
    Daly, L
    Hoogeveen, EK
    Kostense, PJ
    Stehouwer, CDA
    Hopknis, PN
    Jacques, P
    Selhub, J
    Luft, FC
    Jungers, P
    Lindgren, A
    Lolin, YI
    Loehrer, F
    Fowler, B
    Mansoor, MA
    Malinow, MR
    Ducimetiere, P
    Nygard, O
    Refsum, H
    Vollset, SE
    Ueland, PM
    Omenn, GS
    Beresford, SAA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16): : 2015 - 2022
  • [14] Collagen platelet receptor polymorphisms integrin α2β1 C807T and GPVI Q317L and risk of ischemic stroke
    Cole, VJ
    Staton, JM
    Eikelboom, JW
    Hankey, GJ
    Yi, Q
    Shen, Y
    Berndt, MC
    Baker, RI
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) : 963 - 970
  • [15] Cooper JA, 2000, CIRCULATION, V102, P2816
  • [16] Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly
    Crainich, P
    Jenny, NS
    Tang, Z
    Arnold, AM
    Kuller, LH
    Manolio, T
    Sharrett, AR
    Tracy, RP
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) : 1799 - 1804
  • [17] Cushman M, 1998, THROMB HAEMOSTASIS, V79, P912
  • [18] THE HUMAN BETA-FIBRINOGEN PROMOTER CONTAINS A HEPATOCYTE NUCLEAR FACTOR 1-DEPENDENT INTERLEUKIN-6-RESPONSIVE ELEMENT
    DALMON, J
    LAURENT, M
    COURTOIS, G
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (02) : 1183 - 1193
  • [19] Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - Meta-analyses of prospective studies
    Danesh, J
    Collins, R
    Appleby, P
    Peto, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18): : 1477 - 1482
  • [20] GENETIC-VARIATION AT THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 LOCUS IS ASSOCIATED WITH ALTERED LEVELS OF PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY
    DAWSON, S
    HAMSTEN, A
    WIMAN, B
    HENNEY, A
    HUMPHRIES, S
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01): : 183 - 190